Key points
- Claim 1 is a second medical use claim for a combination therapy. Claim 1 has partial priority for only one embodiment. In particular, the priority document discloses only an embodiment with a specific order for administering the medicines.
- D9 is a conference paper published in the priority year. It teaches the medical use (the method of therapy), but not the order of the administration. D9 does not specify the order in which the components of the combination therapy were administered to patients.
- Is claim 1 novel over D9?
- According to the Board, yes, because "Since document D9 fails to disclose an order of administration not covered by the partial priority right conferred by the disclosure in [the priority document], the board considers that the disclosure of document D9 cannot anticipate the subject-matter of claim 1 within the meaning of Article 54 EPC."
- Hence, to anticipate the claim, D9 should have taught an embodiment that is unambiguously outside the part of the claim for which the priority is valid (and that is, also, in accordance with the claim).
- However, the claim is not inventive over D9 as the CPA.
- "Starting from document D9 as the closest prior art, which discloses the use of a FITC-tagged adapter molecule in combination with AT-CAR T cells but does not specify an administration regimen, the skilled person would recognise that document D9 leaves open three alternative possibilities: administering the tagged adapter molecule prior to, simultaneously with or after the AT-CAR T cells. ... The arbitrary selection of one of them does not involve an inventive step."
EPO
The link to the decision is provided after the jump.